C4 Therapeutics Inc.

$CCCC is surging again today and continuing its move from yesterday when the company announced that it had entered into an exclusive licensing and collaboration agreement with Merck ($MRK) to help discover and develop degrader-antibody conjugates (“DACs”), which are designed to selectively target and neutralize disease-causing proteins in cancer cells.

Share This Article

 

About the Author

C4 Therapeutics Inc.

Joey Ramson